fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Triptorelin pamoate

All injection strengths: general benefit

Trelstar (1 Month) · DIN 02240000 · 3.75 mg/Vial · powder for injection, vial

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Trelstar (1 Month) · DIN 02240000 Manufacturer: Knight Therapeutics Inc.; listing date 2007-01-02 Health Canada: Marketed since 2020-09-08 · brand TRELSTAR · ATC L02AE04 TRIPTORELIN · form Powder for suspension (sustained-release · route Intramuscular · ingredients TRIPTORELIN (TRIPTORELIN PAMOATE) 3.75 MG/VIAL · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trelstar (1 Month): Formulary list price $346.31 per unit (the source does not state the unit; exact figure $346.3100). What the ministry pays, not the patient.

Ministry pays: $346.3100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240000)

Source record
DIN 02240000: Trelstar (1 Month) Raw flags: sec3=Y Item: 100000186; group id 188; item number 0344; lccId None; manufacturer id KNT Source form: Inj Pd-Vial Pk; strength: 3.75mg/Vial Recorded listing: General benefit Source prices (unrounded): $346.3100; ministry $346.3100 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240000 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63507
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (L02A, L02AE): coverage varies; not interchangeable

  • Buserelin (Suprefact Depot 2 Months): general benefit
  • Goserelin (Zoladex): general benefit
  • Leuprolide (Lupron Depot PDS): general benefit
  • Megestrol (Megace): general benefit, not a benefit
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

GOSERELIN ACETATE

· 2 products · General benefit · strengths: 3.6mg, 10.8mg · Depot Inj

LEUPROLIDE ACETATE

· 11 products · General benefit · strengths: 3.75mg, 7.5mg, 11.25mg, 22.5mg, 30mg, 3.75mg/Vial, 22.5mg/Vial, 45mg · Inj-Kit, Pd for Inj - Vial Pk, Pd Susp Inj-Pref Syr Kit

MEGESTROL ACETATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg, 160mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications TRELSTAR (triptorelin for injectable suspension) is indicated for: • The management and relief of chronic pain associated with endometriosis. • The palliative treatment of hormone dependent advanced carcinoma of the prostate gland (stage D2). For the management and relief of chronic pain in endometriosis, experience in women has been limited to women 18 years of age or older treated for 6 months. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (≥ 65 years of age): No data are available to Health Canada for the management and relief of chronic pain associated with endometriosis in geriatric patients. The majority of the patients studied in the clinical trials for the palliative treatment of prostate cancer with TRELSTAR were 65 years and older (see 14 Clinical Trials). https://pdf.hres.ca/dpd_pm/00085331.PDF PM date: 2026-07-14 Source product: TRELSTAR; DIN 02240000; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.